Cargando…
Long-term nifekalant use in a patient with dilated cardiomyopathy and recurrent ventricular tachycardia
The potential utility of nifekalant, a new Class III antiarrhythmic drug, to offer long-term protection against ventricular arrhythmia has been investigated in this case report. A 44-year-old male patient with dilated cardiomyopathy complicated with heart failure and persistent ventricular tachycard...
Autores principales: | Xiao, Hongyan, Chen, Qitong, Tao, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620144/ https://www.ncbi.nlm.nih.gov/pubmed/36300319 http://dx.doi.org/10.1177/03000605221133704 |
Ejemplares similares
-
Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia
por: Sato, Shiho, et al.
Publicado: (2017) -
LMNA Gene Mutation Presenting with Ventricular Tachycardia in the Absence of Dilated Cardiomyopathy
por: Poudel, Binod, et al.
Publicado: (2022) -
Bidirectional Ventricular Tachycardia in a Women with Dilated Cardiomyopathy: A Case Report
por: Norwood, Dalton Argean, et al.
Publicado: (2019) -
Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy
por: Chakarov, Ivaylo, et al.
Publicado: (2022) -
Catecholaminergic polymorphic ventricular tachycardia complicated by dilated cardiomyopathy: a case report
por: Christina, Granitz, et al.
Publicado: (2020)